Search Results - "BERESFORD, I. J. M"

The anxiolytic-like activity of GR159897, a non-peptide NK2 receptor antagonist, in rodent and primate models of anxiety by WALSH, D. M, STRATTON, S. C, HARVEY, F. J, BERESFORD, I. J. M, HAGAN, R. M

“…The non-peptide NK2 receptor antagonist, GR159897, was evaluated in two putative models of anxiety, the mouse light-dark box and the marmoset human intruder…”
Get full text

Signalling by CXC‐chemokine receptors 1 and 2 expressed in CHO cells: a comparison of calcium mobilization, inhibition of adenylyl cyclase and stimulation of GTPγS binding induced by IL‐8 and GROα by Hall, David A, Beresford, Isabel J M, Browning, Christopher, Giles, Heather

“…The effect of interleukin‐8 (IL‐8) and growth‐related oncogene α (GROα) on [35S]‐guanosine 5′‐O‐(3‐thiotriphosphate) ([35S]GTPγS) binding, forskolin‐stimulated…”
Get full text

Investigation into species variants in tachykinin NK1 receptors by use of the non‐peptide antagonist, CP‐96,345 by Beresford, I.J.M., Birch, P.J., Hagan, R.M., Ireland, S.J.

“…The affinity of the non‐peptide antagonist CP‐96,345 for tachykinin NK1 receptors has been estimated in a range of species by use of both radioligand binding…”
Get full text

The pharmacology of GR203040, a novel, potent and selective non‐peptide tachykinin NK1 receptor antagonist by Beattie, D.T., Beresford, I.J.M., Connor, H.E., Marshall, F.H., Hawcock, A.B., Hagan, R.M., Bowers, J., Birch, P.J., Ward, P.

“…1 The in vitro and in vivo pharmacology of GR203040 ((2S, 3S)‐2‐methoxy‐5‐tetrazol‐1‐yl‐benzyl‐(2‐phenyl‐piperidin‐3‐yl)‐amine), a novel, highly potent and…”
Get full text

Modulation of the rat suprachiasmatic circadian clock by melatonin in vitro by Starkey, S J, Walker, M P, Beresford, I J, Hagan, R M

“…The pineal hormone melatonin regulates daily and seasonal rhythms, at least in part through an action on the mammalian biological clock in the suprachiasmatic…”
Get more information

Pharmacological characterisation of melatonin mt receptor-mediated stimulation of [35S]-GTPγS binding by BERESFORD, I. J. M, HARVEY, F. J, HALL, D. A, GILES, H

Get full text

GR159897, a potent non-peptide antagonist at tachykinin NK2 receptors by BERESFORD, I. J. M, SHELDRICK, R. L. G, BALL, D. I, TURPIN, M. P, WALSH, D. M, HAWCOCK, A. B, COLEMAN, R. A, HAGAN, R. M, TYERS, M. B

“…GR159897 ((R)-1-[2-(5-fluoro-1H-indol-3-yl)ethyl]-4-methoxy-4- [(phenylsulfinyl)methyl]piperidine) is a novel, highly potent and selective non-peptide…”
Get full text

Novel non-indolic melatonin receptor agonists differentially entrain endogenous melatonin rhythm and increase its amplitude by Drijfhout, Willem J, de Vries, Jan B, Homan, Evert J, Brons, Heleen F, Copinga, Swier, Gruppen, Gert, Beresford, Isabel J.M, Hagan, Russell M, Grol, Cor J, Westerink, Ben H.C

“…In this study we have examined the ability of melatonin and four synthetic melatonin receptor agonists to entrain endogenous melatonin secretion in rats, free…”
Get full text

Anxiolytic activity of tachykinin NK2 receptor antagonists in the mouse light-dark box by Stratton, S C, Beresford, I J, Harvey, F J, Turpin, M P, Hagan, R M, Tyers, M B

“…The tachykinin NK2 receptor antagonists, GR100679 (0.02-200 micrograms/kg s.c.) and (+/-)-SR489698 (0.05-5.0 micrograms/kg s.c.), dose-dependently increased…”
Get more information

Characterisation, CNS distribution and function of NK2 receptors studied using potent NK2 receptor antagonists by Hagan, R M, Beresford, I J, Stables, J, Dupere, J, Stubbs, C M, Elliott, P J, Sheldrick, R L, Chollet, A, Kawashima, E, McElroy, A B

Get more information

Synthesis and Characterization of Selective Fluorescent Ligands for the neurokinin NK2 Receptor by Bradshaw, Charles G, Ceszkowski, Karin, Turcatti, Gerardo, Beresford, Isabel J. M, Chollet, Andre

“…Several fluorescent probes for the NK2 receptor were designed, synthesized, and pharmacologically characterized. These fluorescent ligands are analogues of the…”
Get full text

Receptor-selective, peptidase-resistant agonists at neurokinin NK-1 and NK-2 receptors: new tools for investigating neurokinin function by Hagan, R M, Ireland, S J, Jordan, C C, Beresford, I J, Deal, M J, Ward, P

“…The pharmacological profiles of two novel neurokinin agonists have been investigated. delta Ava[L-Pro9,N-MeLeu10]SP(7-11) (GR73632) and…”
Get more information

Temperature and agonist dependency of tachykinin NK1 receptor antagonist potencies in rat isolated superior cervical ganglion by HAWCOCK, A. B, BERESFORD, I. J. M, MARSHALL, F. H, HAGAN, R. M

“…Using rat isolated superior cervical ganglion we have further characterised tachykinin NK1 receptors and investigated the possible existence of tachykinin NK1…”
Get full text

New spiropiperidines as potent and selective non-peptide tachykinin NK2 receptors antagonists by SMITH, P. W, COOPER, A. W. J, WARD, P, BELL, R, BERESFORD, I. J. M, GORE, P. M, MCELROY, A. B, PRITCHARD, J. M, SAEZ, V, TAYLOR, N. R, SHELDRICK, R. L. G

Get full text

Ontogeny and characterization of [125I]Bolton Hunter-eledoisin binding sites in rat spinal cord by quantitative autoradiography by Beresford, I J, Ireland, S J, Stables, J, Hagan, R M

“…The distribution and characteristics of [125I]Bolton Hunter-eledoisin binding sites in rat lumbar spinal cord were studied during postnatal development by in…”
Get more information

GR138676, a novel peptidic tachykinin antagonist which is potent at NK3 receptors by Stables, J M, Beresford, I J, Arkinstall, S, Ireland, S J, Walsh, D M, Seale, P W, Ward, P, Hagan, R M

“…GR138676, a conformationally constrained analogue of neurokinin B, is a novel, potent NK3 receptor antagonist. GR138676 was a competitive antagonist of…”
Get more information

Experimental hemiparkinsonism in the rat following chronic unilateral infusion of MPP+ into the nigrostriatal dopamine pathway--II. Differential localization of dopamine and cholecystokinin receptors by Beresford, I J, Davenport, A P, Sirinathsinghji, D J, Hall, M D, Hill, R G, Hughes, J

“…The autoradiographical localization of dopamine D1, D2 and cholecystokinin receptors has been investigated in rat brain 6 months following unilateral infusion…”
Get more information

Experimental hemiparkinsonism in the rat following chronic unilateral infusion of MPP+ into the nigrostriatal dopamine pathway--I. Behavioural, neurochemical and histological characterization of the lesion by Sirinathsinghji, D J, Heavens, R P, Richards, S J, Beresford, I J, Hall, M D

“…1-Methyl-4-phenylpyridinium ion (MPP+), the active metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, has been chronically infused (10 micrograms/24 h…”
Get more information

Measurement and characterization of neuronal cholecystokinin using a novel radioreceptor assay by Beresford, I J, Clark, C R, Hughes, J

“…This study describes a novel radioreceptor assay (RRA) for cholecystokinin (CCK) which is the first to measure and characterize brain CCK using a technique not…”
Get more information

Cholecystokinin modulation of [3H]noradrenaline release from superfused hypothalamic slices by Beresford, I J, Hall, M D, Clark, C R, Hill, R G, Hughes, J

“…Interactions between cholecystokinin (CCK) and noradrenaline (NA) have been studied by investigating the effect of sulphated cholecystokinin octapeptide…”
Get more information